RFI Alzheimer’s Research Program (AZRP) Public

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9427RFI2027AZRP

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

-

Additional Details
Set Aside

None

Place of Performance

Frederick, Maryland, UNITED STATES

SourceSAM
Documents2
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a Sources Sought notice (Procurement Identifier: HT9427RFI2027AZRP) to solicit feedback for the Congressionally Directed Medical Research Programs (CDMRP) Alzheimer’s Research Program (AZRP) for fiscal year 2027 (FY27). This Request for Information (RFI) is intended to gather input from a broad spectrum of stakeholders—including academia, industry, community and non-profit organizations, scientific and professional bodies, federal agencies, and the general public—to inform the strategic planning and research focus areas for the upcoming AZRP funding cycle. The primary purpose of this RFI is to support the development of impactful and solution-oriented research initiatives aimed at mitigating the effects of Alzheimer’s disease and related dementias, particularly those associated with traumatic brain injury (TBI), military service, and diverse risk factors. The AZRP’s mission is to address critical needs and improve the quality of life for Service Members, Veterans, their families, and the broader public affected by these conditions. It is important to note that, as of October 2026, federal appropriations for the FY27 AZRP have not been secured. The information collected through this RFI is solely for strategic planning purposes and does not constitute a solicitation or a commitment to incorporate the feedback into future funding opportunities. Respondents should be aware that participation in this RFI does not obligate the AZRP or the Department of War (DoW) to any subsequent procurement actions. The AZRP has historically received significant congressional support, with appropriations totaling $228 million from FY11 through FY26. Should funding be appropriated for FY27, the CDMRP will employ its established two-tier review process to manage the program efficiently. Additional background and program details are available on the CDMRP AZRP website. The scope of this RFI falls under NAICS Code 541714, which covers Research and Development in Biotechnology (except Nanobiotechnology). The place of performance is Frederick, Maryland, USA. The contracting entity is the Defense Health Agency, a federal office within the Department of Defense. Interested parties are encouraged to provide their input by responding to the survey linked in the notice (https://www.surveymonkey.com/r/FY27-AZRP-RFI) by December 4, 2026. For further information or inquiries, the primary point of contact is Jared D. Acre, who can be reached at [email protected] or by phone at 301-619-9033. This RFI represents an opportunity for stakeholders to influence the direction of future Alzheimer’s research funding priorities within the military and public health context. Contractors and organizations with expertise in biotechnology research, particularly those focused on neurodegenerative diseases and military health, may find this engagement aligns with their capabilities and strategic interests, though it is not a solicitation for proposals or bids at this stage.